Daratumumab interference with immunohematology testing in a nonmultiple myeloma neutropenic patient, in need of granulocyte transfusion

Daratumumab interference with immunohematology testing in a nonmultiple myeloma neutropenic patient, in need of granulocyte transfusion

Daratumumab (DARA) may interfere with immunohematology tests by binding to endogenous CD38 present on the surface of the red blood cells. DARA was Food and Drug Administration approved for refractory multiple myeloma patients, but now its application is being explored in other oncology patients also...

Full description

Bibliographic Details
Main Authors: Abhaykumar Malind Gupta, Shashank Ojha, Amol Tirlotkar, Vimal Sathyan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Global Journal of Transfusion Medicine
Subjects:
anti-cd38
compatibility testing
daratumumab
dithiothreitol
serology interference
Online Access:http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2021;volume=6;issue=1;spage=103;epage=105;aulast=Gupta

Internet

http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2021;volume=6;issue=1;spage=103;epage=105;aulast=Gupta

Similar Items